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ABSTRACT
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare 
and heterogeneous tumors, and their biological behavior is not well known. We 
studied the presence and potential functional roles of somatostatin receptors (sst1-5),  
focusing particularly on the truncated variants (sst5TMD4, sst5TMD5) and on their 
relationships with the angiogenic system (Ang/Tie-2 and VEGF) in human GEP-NETs. 
Experimental Design: We evaluated 42 tumor tissue samples (26 primary/16 
metastatic) from 26 patients with GEP-NETs, and 30 non-tumoral tissues (26 from 
adjacent non-tumor regions and 4 from normal controls) from a single center. 
Expression of sst1-5, sst5TMD4, sst5TMD5, Ang1-2, Tie-2 and VEGF was analyzed 
using real-time qPCR, immunofluorescence and immunohistochemistry. Expression 
levels were associated with tumor characteristics and clinical outcomes. Functional 
role of sst5TMD4 was analyzed in GEP-NET cell lines.
Results: sst1 exhibited the highest expression in GEP-NET, whilst sst2 was the 
most frequently observed sst-subtype (90.2%). Expression levels of sst1, sst2, sst3, 
sst5TMD4, and sst5TMD5 were significantly higher in tumor tissues compared to 
their adjacent non-tumoral tissue. Lymph-node metastases expressed higher levels 
of sst5TMD4 than in its corresponding primary tumor tissue. sst5TMD4 was also 
significantly higher in intestinal tumor tissues from patients with residual disease 
of intestinal origin compared to those with non-residual disease. Functional assays 
demonstrated that the presence of sst5TMD4 was associated to enhanced malignant 
features in GEP-NET cells. Angiogenic markers correlated positively with sst5TMD4, 
which was confirmed by immunohistochemical/fluorescence studies.
Conclusions: sst5TMD4 is overexpressed in GEP-NETs and is associated to 
enhanced aggressiveness, suggesting its potential value as biomarker and target in 
GEP-NETs.
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INTRODUCTION
Neuroendocrine tumors (NETs) comprise a 
heterogeneous group of neoplasms derived from 
enterochromaffin epithelial cells, which retain many 
structural and functional features of normal endocrine 
cells, including production of chromogranin A (CgA), 
synaptophysin, and other peptides [1]. The majority 
of these tumors are of gastro-entero-pancreatic origin 
(GEP-NET) and, although they were initially believed to 
be uncommon neoplasms, their incidence and prevalence 
is increasing, and not only because of improved imaging 
techniques [2].
Unlike other malignancies, the natural history of 
NETs is significantly variable and difficult to predict. 
Most patients with well-differentiated GEP-NETs, even if 
metastatic disease is present at diagnosis, may present with 
a relatively indolent course, whilst others may progress 
rapidly, with median survival duration ranging from 5 to 
56 months in advanced stage disease [2]. To date, there are 
very few biomarkers of prognosis, which could be useful 
to assess prognosis and select patients whose disease may 
progress rapidly or who may benefit from early initiation 
of therapy [3].
Although the first therapeutic option for GEP-NETs 
is the surgical approach, complete cure is not possible 
in many cases, and development of systemic medical 
treatments has gained scientific and clinical interest over 
the past recent years. In this setting, synthetic somatostatin 
analogues (SSAs) have emerged as a successful tool for 
the management of neuroendocrine diseases [4, 5]. SSAs 
inhibit hormonal secretion by binding to ssts, and thus 
provide relief of symptoms in patients with functional 
NETs. Additionally, they exert antitumor effects; this was 
confirmed by the results of the PROMID study [6], which 
reported a significant increase in time to tumor progression 
in functionally active and inactive tumors; and in a more 
evident way, in the recent CLARINET study, which 
further reported an increase in median progression-free 
survival in SSA-treated patients [7].
SSAs exert their biological actions by binding to 
a family of G protein-coupled, seven transmembrane-
spanning somatostatin receptors (sst1-sst5) in 
neuroendocrine cells, which, depending on the tumor type 
and the specific set of receptors involved, lead to decreased 
hormonal secretion, decreased growth and mitotic rates, 
increased apoptosis, and/or inhibition of cell signaling and 
protein synthesis, including inhibition of production and 
secretion of various angiogenic factors [8–11]. In mammals, 
ssts are encoded by five separate intronless genes (SSTR1-
SSTR5), which have been classically considered to give 
rise to five different somatostatin receptors, named sst1 
through sst5, plus, in mouse, a carboxyterminal spliced 
variant of sst2, named sst2B. However, recent studies from 
our group have unveiled the existence of new truncated, 
albeit functional sst5 variants, generated by non-canonical 
splicing, which in humans bear 5 and 4 transmembrane 
domains (instead of the usual 7), and are therefore referred 
to as sst5TMD4 and sst5TMD5 [12, 13].
As sst subtypes represent obligatory mediators of 
SSA actions, variability in the sst1-5 expression profile in 
NET cells has been reasonably suggested as a potential 
predictive factor for SSA response. In fact, antiproliferative 
effects of SSAs have been associated to their affinity 
for sst2 [14, 15]; and conversely, the tachyphylaxis that 
eventually develops in some cases during long-term 
management of NETs has been attributed to a possible 
loss of sst2 availability following receptor internalization 
and degradation [16]. Moreover, since antisecretory and 
antiproliferative effects occur at different time-windows, 
involvement of different receptors and/or molecular 
mechanisms has been also proposed [17]. For instance, 
the presence of the truncated variant sst5TMD4, which 
interacts with sst2 and disrupts its signaling [18], may 
influence spontaneous or SSA-inhibited hormone secretion 
[19], as well as aberrant cell proliferation [18, 20], 
and has been proposed as a biomarker for increased risk of 
malignant behavior in certain tumors [18, 20, 21].
Another issue deserving further investigation in 
GEP-NETs concerns angiogenesis, since formation of new 
vessels from pre-existing vasculature is crucial for local 
invasion and metastatic spread of tumors. Molecules that 
exert important regulatory roles in angiogenesis in NETs 
include the vascular endothelial growth factor (VEGF), 
angiopoietins (Ang)-1 and -2, and the tyrosine kinase 
receptor Tie-2 (or Tek) family [22–24]. VEGF acts as a 
pro-angiogenic factor on vascular endothelium, inducing 
proliferation and new micro-vessel formation. Meanwhile, 
soluble angiopoietins, which are secreted by endothelial 
and epithelial cells in response to stress, hypoxia and 
inflammation, bind to Tie-2 to fulfill their actions. 
Specifically, Ang-1 promotes endothelial cell survival, 
and anti-inflammatory and anti-permeable effects [23–25], 
whilst Ang-2 causes vasculature regression or a marked pro-
angiogenic effect if VEGF is present. Thus, the Ang/Tie2 
system seems to play an important role in vascular network 
remodeling [26] and in the pathogenesis and progression 
of NETs [27]. Furthermore, a potential relationship of this 
angiopoietic system with SSA and their binding to ssts may 
also exist [28–33], although the precise roles of the different 
components of these systems and the potential interactions 
between them are insufficiently characterized.
Therefore, in this study, we aimed to determine 
the presence and potential functional roles of the novel 
truncated sst5 variants, and their association with the 
VEGF and Ang/Tie system, in human GEP-NETs.
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RESULTS
A total of 26 patients with GEP-NET were included in 
our study. Thirteen patients (50%) presented with pancreatic 
tumors (7 non-functional, 5 insulinomas and 1 ectopic 
Cushing) and the other 13 had gastrointestinal NETs. A 
total of 15 patients presented with metastasis, the majority 
of them in regional lymph nodes and/or liver. Pre-surgical 
CgA was determined in 22 patients, with a mean value of 
19.7 ± 21.2 nmol/L (median 15.3 (0–77) nmol/L; reference range 
0–6 nmol/L). Pre-surgical 5-hydroxy-indoleacetic acid was 
available in 8 patients, with a mean value of 17.2 ± 17.6 mg/24 h 
(median 7.8 (2–42) mg/24 h; reference range 2–10 mg/24 h). 
Immunoperoxidase staining for CgA and synaptophysin 
was positive in all tumor tissues. A Ki-67 immunoreactivity 
level > 2% was observed in 7 out of the 14 available samples 
(mean Ki 67 index 10.7 ± 23.3 %; median 2.5 (2–90)%). A 
detailed summary of clinical and pathological features of the 
patients included in our study is shown in Table 1.
SST receptors and the truncated variants are 
overexpressed in GEP-NETs
qPCR in GEP-NET revealed expression of sst1 in 
80.8% of cases, sst2 in 92.0%, sst3 in 56.0%, sst4 in 68.0%, 
and sst5 in 68.0%. Receptor subtype sst1 exhibited the highest 
expression in GEP-NET, followed by sst2 > sst4 > sst3. 
A significant increase in expression levels of sst1, sst2 
and sst3 was observed in tumor tissues in comparison to 
adjacent non-tumor tissues (3.88 ± 2.23 vs. 0.02 ± 0.01; 
0.62 ± 0.08 vs. 0.24 ± 0.08; and 0.09 ± 0.02 vs. 0.04 ± 0.02, 
respectively). However, no significant differences were 
observed in the expression of sst4 and sst5 between tumor 
and non-tumor samples (Figure 1). Interestingly, expression 
of the truncated subtypes sst5TMD4 and sst5TMD5 was 
detected in 25 and 19 cases, respectively, out of the 26 
tumor samples evaluated (96.2% and 73.1%, respectively), 
whilst analysis of these receptors in adjacent, non-tumor/
control tissues evidenced detectable expression in only 
65.5% and 17.2% of cases, respectively (Table 2). Moreover, 
qPCR revealed an increased expression in tumor tissues in 
comparison to normal tissues (0.15 ± 0.05 vs. 0.08 ± 0.05, 
p < 0.01 for sst5MD4, and 0.011 ± 0.005 vs. 0.0006 ± 0.0004, 
p < 0.001 for sst5TMD5) (Figure 1). No statistical differences 
were found between normal tissue and adjacent “normal” 
tissue in the vicinity of the NET (Supplementary Figure 1). 
However, it is worth noticing that three of these adjacent 
non-tumor tissues (two of which were samples from liver 
metastases) had a high expression (outliers by Tukey’s 
method) of the truncated variants. In agreement with this 
finding, immunohistochemical analysis of serial sections of 
normal (healthy) pancreas samples demonstrated that normal 
pancreatic islets (stained for CgA) did not show an evident 
sst5TMD4 specific staining (Supplementary Figure 2).
Expression of SST and CORT was detected in 
66.7% and 56.0% respectively (Table 1) but no significant 
differences in their expression were found between tumor 
and non-tumor samples (Supplementary Figure 3).
sst5TMD4 is associated to enhanced malignancy 
features in patients with GEP-NETs and 
transfected cell lines
Tumor tissues from gastrointestinal origin from 
patients with residual disease analyzed by qPCR exhibited 
higher expression of sst5TMD4, compared to those tumors 
from patients with non-residual disease (Figure 2A). 
However, no significant differences were found in tumors 
from pancreatic origin. Furthermore, a comparative 
analysis of the sst subtypes and their variants in paired 
biopsies from primary- and metastatic-site tumor tissues 
from the same patients revealed an increased expression 
of sst5TMD4 in lymph-node metastases, in comparison to 
its original corresponding primary tumor (Figure 2B). In 
contrast, there was no difference in sst receptor expression 
between distant metastases and their corresponding 
primary tumor (p > 0.05; 5 pairs analyzed). 
Expression of SST, CORT and both canonical and 
truncated ssts was also analyzed in BON-1 and QGP-1 cell 
lines by qPCR, which are commonly accepted as useful 
models for NET cell studies (Figure 3). Consistent with its 
origin from a human somatostatinoma, expression of SST 
was elevated in QGP-1 cells in comparison to CORT, but 
this was not the case for BON-1 cells (Figure 3A). When 
analyzing the different subtype receptors, we observed that 
sst5 showed the highest expression in both cell lines, while 
BON-1 presented moderate levels of both sst1 and sst3 
(Figure 3A). Interestingly, both cell lines exhibited similar 
low levels of sst2 (Figure 3A). However, it is worth noting 
that truncated receptors were not detectable in any of these 
cell lines (Figure 3A). Thus, to further assess the potential 
impact of sst5TMD4 on malignancy features in NETs, we 
induced its overexpression in QGP-1 and BON-1 cell lines 
by sst5TMD4-vector transfection. qPCR of transfected 
cells confirmed successful transfection in both cell lines, 
where a high number of mRNA copies of sst5TMD4 was 
detected (Figure 3B and 3C – first panel). Using these cells 
as a model, we observed that proliferation rate at 48 h was 
significantly higher in BON-1 sst5TMD4-transfected cells 
(Figure 3B – second panel) than in controls. In contrast, 
no such differences in the proliferation rate were found 
between mock and sst5TMD4-transfected QGP-1 cells 
(Figure 3C – second panel). In agreement with this finding, 
a significant increase in Ki67 expression was observed in 
BON-1 sst5TMD4-transfected cells, but not in QGP-1 cells 
(Figure 3B and 3C – third panel). Further functional assays 
revealed that the presence of sst5TMD4 induced similar 
changes in both cell lines regarding their aggressiveness, 
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Table 1: Clinical, laboratory and pathological features of the 26 patients with gastro-entero-
pancreatic neuroendocrine tumors
PATIENT S A Tumor Type
Stage 
(ENETS)
WHO 
Grade
Metastasis 
(Location)
Presur-
gery 
CgA*
(nmol/L)
Presurgery 
Urinary 
5-HIAA**
(mg/24 h)
Presur-
gery 
Octreo-
scan
Postsur-
gical SSA 
Treat-
ment
Follow-
up***
1 F 34 P IIA G2 ND − Negative − ND
2 F 41 P IIIB − RLN 0 − Negative − ND
3 F 67 P I −  0 − − − ND
4 F 53 G IIA − ND − − − ND
5 F 76 P IV − RLN, L 5 4 Positive + RD
6 M 38 G IV − RLN, L 0 42 Positive + RD
7 F 78 P IV − RLN, L 33 − Positive + RD
8† M 58 P IV − RLN, L, P 33 3 Positive + RD
9 F 78 G IV G1 RLN, L 6 − Positive + RD
10 M 41 G IV G2  3 2 Negative + RD
11 F 71 P I G1 6 − Negative − ND
12† F 57 G IV G2 RLN, L, 
LM, B
59 32 Positive + RD
13 M 58 G IV G1 RLN, L 77 − Positive + RD
14 F 73 P IV G2 L 18 − Negative + RD
15 M 54 G IV G2  RLN, L 15 12 Negative + RD
16† F 66 G IIB −  1 4 Negative − ND
17 F 44 G IIB G1 15 − − − ND
18 M 58 G IIIB G1 RLN 1 − − − ND
19 M 63 G IV G1 RLN, L 18 − Positive + RD
20† M 85 P I G3  8 − − - ND
21 M 79 P I − 22 − Positive - ND
22† F 51 G IV - RLN, L 46 − Positive + RD
23 F 49 P I G1  22 − − − ND
24 M 43 P IIB −  46 − − − ND
25 F 44 P I G2 ND − − − ND
26 M 58 G IV − RLN, L ND 40 Positive + RD
Abbreviations: S: sex; A: age; CgA: chromogranin A; 5-HIAA: 5-hydroxy-indoleacetic acid; SSA: somatostatin analogues; M: 
male; F: female; P: pancreatic NET; G: gastrointestinal NET; RLN: regional lymph nodes; L: liver; P: peritoneum; LM: lung; 
NA: not available. †: patients died during follow-up. *CgA Range: 1–6 nmol/L.**5-HIAA Range: 2–10 mg/24 h. ***ND: 
non-residual disease, if there was a complete resection after surgery and no tumor relapse was evidenced during follow-up; 
RD: residual disease, in cases of tumor burden after surgery or relapse of disease during follow-up. Median follow-up was 
87.5 months (19–214).
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Table 2: Number of samples (%) in which somatostatin receptors were detected
Tumor tissue Adjacent non-tumor/control tissue
sst1 21/26 (80.8) 14/28 (50.0)
sst2 23/26 (92.0) 17/28 (60.7)
sst3 14/25 (56.0) 12/26 (46.2)
sst4 17/25 (68.0) 14/26 (53.8)
sst5 17/25 (68.0) 13/26 (50.0)
sst5TMD4 25/26 (96.2) 19/29 (65.5)
sst5TMD5 19/26 (73.1) 5/29 (17.2)
SST 22/26 (84.6) 19/26 (61.5)
CORT 16/24 (66.7) 14/25 (56.0)
Figure 1: Expression of somatostatin receptors in GEP-NETs and adjacent non-tumor tissue. Canonical (sst1–5) and 
truncated (sst5TMD4 and sst5TMD5) somatostatin receptors were measured by qPCR in a set of GEP-NETs, including primary and 
metastatic tissue. Values represent mean ± SEM of absolute mRNA values, adjusted by β-actin. Asterisks indicate significant differences 
between tumor and adjacent non-tumor tissues (p-values for t-test: *p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 3: The presence of sst5TMD4 is associated to enhanced malignant features in NET cell lines. (A) Normalized levels 
of SST, CORT and sst expression in BON-1 NET cell lines and QGP-1 NET cell lines. Functional assays in sst5TMD4-transfected BON-1 
cell lines (B) and QGP-1 cell lines (C) in comparison to mock cells. Panel order from left to right: sst5TMD4 overexpression; proliferation 
rate; Ki67 expression; migration capacity; and serotonin secretion. Values represent mean ± standard error of the mean. Asterisks indicate 
significant differences (p-values for t-test: *p < 0.05, **p < 0.01, ***p < 0.001).
Figure 2: Expression of sst5TMD4 is associated to increased malignancy in patients with GEP-NETs. (A) mRNA expression 
levels of sst5TMD4 in tumor samples of gastrointestinal origin. Patients were classified according to disease status in non-residual and 
residual disease. Values represent mean ± SEM of absolute mRNA values, adjusted by β-actin. (B): Paired analysis of sst5TMD4 expression 
in primary tumor tissue and lymph-node metastases of the same patients. Absolute mRNA level values were determined by qPCR and 
adjusted by β-actin. 1 was an intestinal tumor and 4 were pancreatic. Asterisks indicate significant differences (p-values for t-test: *p < 0.05).
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since we could observe that sst5TMD4-transfected 
cells, but not mock cells, exhibited higher migration 
capacity (Figure 3B and 3C – fourth panel). In addition, 
functional capacity of sst5TMD4 transfected cells 
was higher as an increased serotonin secretion in 
comparison to mock cells was found (Figure 3B and 
3C – fifth panel).
Expression of truncated receptors correlates 
with expression of angiogenic markers in 
patients with GEP-NET
Specific qPCR analysis for angiogenic markers 
confirmed the presence of Ang-1, Ang-2, Tie-2 and 
VEGF in GEP-NET (Figure 4). In addition, serial 
immunohistochemistry with specific antibodies in paraffin-
embedded tissues from both pancreatic and gastrointestinal 
NETs, evidenced positivity for Ang-1, Ang-2 Tie-2 and 
sst5TMD4 in tumoral cells in serial sections (Figure 5A). 
IHS was evaluated in 16 tumor samples (14 primary and 
2 metastatic). High expression of sst5TMD4 was found in 
50% (7/14) of primary tissues and 100% (2/2) of metastatic 
tissues. Median IHS values were 100 (range 0–300) 
for sst5TMD4, 208 (70–300) for Ang-1, 185 (60–270) 
for Ang-2, and 189 (80–285) for Tie-2. These results were 
corroborated by triple immunofluorescence studies (Figure 
5B). We observed co-expression of sst5TMD4 (Figure 5B 
lane 2 and 3) and CgA in neuroendocrine tumor cells, 
but not in adjacent non-tumor cells (Figure 5B lane 4). 
In addition, co-expression of sst5TMD4 and different 
angiogenic markers was also evidenced in neuroendocrine 
cells (Figure 5B lane 6). Spearman’s Rho analyses in 
tumor tissues revealed positive significant correlations 
between the four angiogenic markers, and a negative 
correlation of each one of them with receptor subtypes 
sst3 and sst4 (Figure 6). Furthermore, Ang-1, Ang2, Tie-2 
and VEGF were all directly and significantly correlated 
with sst5TMD4, and Tie-2 showed this same relationship 
with sst5TMD5 (Figure 6 – bottom left). On the contrary, 
however, in the few samples of adjacent non-tumor tissue 
in which sst5TMD4 and VEGF were detected, positive 
correlations were only observed for Ang-1 and Ang-2, and 
VEGF with Ang-1 and sst5TMD4 (Figure 6 – top right). 
In view of these results, the expression of these pro-
angiogenic factors and the secretion of VEGF were 
determined in mock and sst5TMD4-transfected BON-1 
and QGP-1 cells. As shown in Supplementary Figure 
4, sst5TMD4 overexpression in both cell lines did not 
increase the expression of pro-angiogenic factors (VEGF, 
Ang-1 or Ang-2) or the release of VEGF to the culture 
media.
DISCUSSION
In this study, we have investigated the expression 
pattern of somatostatin receptors, particularly their 
truncated sst5 variants, as well as key markers of 
angiogenesis in a group of patients with GEP-NET. 
Additionally, we have evaluated their potential functional 
relationship. To our knowledge, this is the first time in 
which this has been thoroughly analyzed in a relatively 
large series of samples, especially when considering the 
limited prevalence of this uncommon heterogeneous group 
of neoplasms.
In the present series, we observed a differential sst 
expression pattern in tumor samples compared to their 
corresponding adjacent non-tumor tissues. Specifically, 
sst1–3 were significantly overexpressed in tumor samples 
in comparison to adjacent non-tumoral tissue. Our 
observations confirm previous reports and add further 
information regarding canonical somatostatin receptors 
(sst1–5) [9, 42, 43]. On this basis, it is worth emphasizing 
that identifying the potential influence of sst5TMD4 and 
sst5TMD5 in GEP-NET may entail important clinical 
Figure 4: Expression of angiogenic molecules/markers in GEP-NETs and adjacent non-tumor tissue. mRNA expression 
(fold induction) of Ang-1, Ang-2, Tie-2 and VEGF was measured by qPCR in a set of GEP-NETs, including primary and metastatic tissue. 
Results were normalized according to the value of β-actin. Values represent mean ± standard error of the mean.
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Figure 5: Expression of sst5TMD4 and co-localization with angiogenic marker in GEP-NET. (A) Analysis of expression of 
angiogenic molecules and sst5TMD4 by specific serial immunohistochemistry in a pancreatic NET. Original magnification ×100 and ×400 
(insets). N: normal tissue; T: tumor tissue. For specific immunostaining techniques see the “Materials and methods” section. (B) Expression 
of sst5TMD4 and angiogenic molecules by triple immunofluorescence in a gastrointestinal NET sample. Original magnification ×400. N: 
normal tissue; T: tumor tissue. For specific immunofluorescence techniques see the “Materials and methods” section. Scale bar for 100 µm 
is represented with a line for each Figure.
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consequences, especially given the fact that SSA treatment 
is virtually standardized in medical practice following 
non-curative surgery of GEP-NET [37].
A relevant finding of our study was that these 
truncated variants of sst5 were associated to enhanced 
malignancy features. Firstly, we found an association 
between the expression of these canonic receptors and 
disease status, with sst5TMD4 being higher in those 
tumors from patients with gastrointestinal NETs and 
residual disease, compared to those with non-residual 
disease after surgery. Residual disease includes invasive 
and/or disseminated tumors, either because they were not 
resectable by surgery or due to tumor recurrence after a 
prior complete resection. Therefore, our findings suggest 
a possible link between sst5TMD4 and worse clinical 
outcome. Secondly, paired analyses identified an increased 
expression of sst5TMD4 in metastatic lymph nodes in 
comparison to their corresponding primary tumors. This 
suggests that primary tumors expressing sst5TMD4 could 
potentially develop lymph node metastasis and/or local 
progression more frequently. Indeed, functional assays 
with sst5TMD4-trasfected BON-1 cells of carcinoid 
origin evidenced an increased proliferation rate and Ki67 
expression. Interestingly, although sst5TMD4-trasfected 
QGP-1 cells did not mimic these results, presumably 
due to their different nature (i.e. the considerable SST 
expression in the latter), both sst5TMD4-trasfected NET 
cell lines exhibited higher migration capacity. Moreover, 
transfected cells preserved their ability to secrete serotonin 
and, in fact, serotonin levels were significantly increased 
in these cells. 
In a previous study, we demonstrated that 
transfection of sst5TMD4 in MCF-7 cells, a model 
for breast cancer, increased expression of Arp-2/3 
(Actin-related proteins) [18], a complex that plays a 
major role in the regulation of actin filaments, and is 
associated to the enhanced ability of cancer cells to invade 
[44]. Also, in this same model, we found that cells with 
endogenous expression of sst5TMD4 showed higher 
levels of p-Akt and p-ERK1/2, two kinases that activate 
signal transduction pathways involved in proliferation, 
migration and phenotype transformation in cancer cells. 
Furthermore, we have recently reported sst5TMD4 
overexpression in thyroid cancer, both medullary and 
non-medullary [20, 21]. sst5TMD4 overexpression in TT 
cells confers a greater growth capacity, modifies the cell’s 
phenotype, decreases E-cadherin and phosphorylated 
β-catenin levels, increases vimentin, total β-catenin and 
phosphorylated GSK3B levels, and confers a greater 
invasion capacity [21].
There are other profoundly complex molecular 
pathways involved in the pathogenesis of GEP-NETs. 
For instance, dysregulation of the phosphoinositide 
3-kinase (PI3K)-Akt-mTOR pathway [45], or aberrant 
Figure 6: Heat-Maps for correlations between the expression of SST and angiogenesis systems (Spearman’s Rho). 
Significant negative correlations are shown in red and significant positive correlations in green. Bottom left triangle shows correlations 
in tumor tissues and top-right hand triangle shows correlations in non-tumor adjacent tissues. In tumor samples, SST and CORT showed 
a significant positive correlation with sst1-5, and these subtypes were also positively correlated between themselves in a significant way. 
sst5TMD4 showed a positive correlation with SST and sst1, and sst5TMD5 with sst1. A positive correlation was found between the 
four angiogenic makers and a negative one between each one of them and sst3 and sst4. Ang-1, Ang-2, Tie-2 and VEGF were positively 
correlated with sst5MD4. Analyses of correlations in adjacent non-tumor tissues showed similar findings regarding CORT and sst1–5. 
However, SST was only correlated with sst5, and no correlation was observed between truncated receptors and the rest of subtypes. 
Asterisks mark significant p-values (*p < 0.05, **p < 0.01, two-sided).
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signaling through G protein-coupled receptors like 
ssts, may lead to modulation of several key enzymes, 
including adenylyl cyclase, phosphotyrosine phosphatases 
(PTPs) and MAPKs (mitogen activated kinases) [46–48]. 
In this complex molecular scenario, it seems biologically 
plausible that sst5TMD4 plays a relevant role in the 
specific setting of GEP-NET, since, despite being a 
truncated receptor variant, it can influence and interfere 
with subsequent regulation of several molecular pathways. 
Although further investigations regarding these complex 
molecular relationships deem necessary to clarify this 
issue, sst5TMD4 may be indeed associated to tumor 
progression and possibly a worse clinical outcome in 
GEP-NET.
Given the vascular nature of NETs, which has been 
demonstrated in different experimental models [27, 49], 
angiogenesis is likely to play a relevant role in the 
pathogenesis and progression of GEP-NET. In this regard, 
we confirmed the presence of key angiogenic markers, 
Ang-1, Ang-2, Tie-2 and VEGF, in tumor samples from 
patients with GEP-NET and in transfected cell lines. 
Further, tumor expression of these markers showed 
a positive correlation between them, and a negative 
correlation with subtypes sst3 and sst4, in agreement with 
the above-mentioned studies. Interestingly, in addition, we 
report another novel finding: expression of the truncated 
variant sst5TMD4 was positively correlated with all 
four angiogenic markers. Immunohistochemical and 
immunofluorescence studies confirmed co-expression of 
angiogenic markers and of sst5TMD4 in CgA+ tumor cells. 
Furthermore, immunohistochemical analysis of normal 
(healthy) pancreatic tissue did not evidence a detectable 
expression of sst5TMD4 in CgA+ islet cells. These results 
further support the hypothesis of the potential interference 
of this variant in the putative signaling pathway of 
canonic non-truncated sst subtypes, as it has been 
proposed in earlier studies [18], as well as with angiogenic 
molecules, as also suggested by our present data. SSAs 
are known to exert an anti-angiogenic effect through 
their interaction with ssts, by inhibiting production 
and secretion of many angiogenic factors [10, 11]. 
In this context, previous studies have reported that 
signaling through sst3 down-regulates VEGF production 
[29], that sst1 signaling inhibits endothelial proliferation, 
migration and neovascularization [32, 50], and that, 
through sst1-3, the endothelial nitric oxide synthase 
(NOS) is inhibited [29, 30]. Moreover, sst2 expression 
has been shown to have an anti-angiogenic role in animal 
models of hypoxia [51], suggesting an active interplay 
between the somatostatin-signaling network and sustained 
angiogenesis. Also, somatostatin secretion is known to 
negatively influence VEGF production [52], and in vitro 
experiments have shown that the administration of the 
SSA octreotide can antagonize the hypoxia inducible 
factor 1a (Hif-1a) transcriptional activity in NET cells 
[8]. In line with these reports, our present findings favor 
the hypothesis that sst5TMD4 could play an important 
role in the complex molecular network of vascularization 
signaling. Specifically, if we take into account the fact 
that sst5TMD4 interacts with sst2 [18, 19], the subsequent 
decreased and/or abnormal activation of sst2-associated 
transduction signaling pathways would plausibly lead to 
the development of increased vascularization, by reducing 
its usual antiangiogenic effect.
Although we acknowledge the limitations of our 
study regarding the number of samples evaluated and 
its retrospective observational nature, we would like to 
highlight the fact that, to our knowledge, this is one of 
the largest GEP-NET series in which such a thorough 
qPCR analysis of sst subtypes, including the truncated 
variants, and angiogenesis-related molecular markers has 
been performed. Besides, we should also bear in mind 
that analysis of surrounding non-tumoral tissue, adjacent 
to each corresponding tumor, is not the ideal method for 
comparison with tumor tissue in the case of NETs, as it 
has been widely recognized in this research field; this 
should be considered only as a reference tissue, rather 
than as a genuine control, but it serves for the purpose of 
investigations in this topic. 
In conclusion, we report for the first time a 
significant overexpression of the truncated variants 
sst5TMD4 and sst5TMD5 in GEP-NET, as well as 
increased levels of sst5TMD4 in patients with residual 
gastrointestinal NET and in lymph-node metastases, 
in relation to its corresponding primary tumor tissue. 
sst5TMD4 was associated to an enhanced proliferation 
rate, migration capacity and serotonin secretion in NET 
model cell lines, and to a relationship with angiogenic 
markers in tumor tissues. Taken together, our results 
suggest that the truncated variant sst5TMD4 could be 
involved in local progression and worsen prognosis in 
GEP-NET. Results of our various analyses contribute to 
a better characterization and knowledge of GEP-NET, 
and allow more accurate and evidence-based prognostic 
estimations. Further long-term and prospective studies 
deem necessary to better understand the relevance of 
these ssts subtypes, specially the truncated sst5 variants, 
in the pathophysiology and clinical/prognostic features of 
GEP-NET. 
MATERIALS AND METHODS
Study population
We reviewed 26 consecutive patients (15, 57.7% 
females, mean age 58.4 ± 14.4 years old) with GEP-NET 
who underwent surgery at our center from 2001 to 2009. 
All patients were carefully screened for the presence 
of other malignancies, and special attention was paid 
for an association with genetic syndromes (multiple 
endocrine neoplasia type 1, von Hippel-Lindau syndrome, 
tuberosclerosis and neurofibromatosis syndromes). Only 
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one patient carried a mutation for multiple endocrine 
neoplasia type 1.
Data regarding physical examination, medical 
history, and laboratory work-up were obtained from 
routine visits using information available in clinical 
records. Patients were classified according to the ENETS 
and WHO criteria (tumor site and size, Ki67, mitotic 
rate and metastases) [34, 35]. Additionally, according to 
histopathology findings, all well-differentiated neoplasms 
were classified as NETs and graded G1 (Ki67 < 2%) or 
G2 (Ki67 2–20%), and all poorly differentiated neoplasms 
were designated as neuroendocrine carcinomas (NECs) 
and graded G3 (Ki67 > 20%) [36].
Patients were managed following current 
recommendations and guidelines [37]. Elective surgery 
was the first option of treatment in all cases and adjuvant 
therapy with SSAs was administered if evidence of 
residual disease was observed. Follow-up evaluation 
classified patients into two categories according to their 
clinical status: 1) non-residual disease, if a complete 
resection after surgery had been achieved and no tumor 
relapse was evidenced during follow-up and 2) residual 
disease, in cases of tumor burden after surgery or relapse 
of disease during follow-up. The median of follow-up was 
87.5 months (19–214).
The study was approved by the local Ethical 
Committee and conducted in accordance to the principles 
of the Declaration of Helsinki, and all patients signed a 
written informed consent before inclusion.
Samples
A total of 72 formalin-fixed paraffin-embedded 
tissues were evaluated. Of these, 42 were proper tumor 
samples with pathological diagnosis of NET (26 from 
the primary site and 16 from a metastatic site), and 30 
corresponded to normal tissues (26 samples form adjacent 
non-tumor regions and 4 normal control tissues that 
had been obtained from patients undergoing pancreatic, 
intestinal or hepatic resection), which were used as 
qRT-PCR negative controls. Additionally, three normal 
pancreatic tissues were used as immunohistochemistry 
negative controls. All samples were taken and managed 
in accordance with regulations and approval of the local 
Institutional Review Board.
A thorough review of hematoxylin and eosin 
(H&E) sections by a board-certified endocrine pathologist 
(MA) was carried out to ensure identification of relevant 
and representative areas of tumor and non-tumor 
tissues to proceed to RNA extraction. Simultaneously, 
immunohistochemical staining was performed in paraffin 
embedded blocks by the avidin-biotin peroxidase complex 
(ABC) method, using anti-human CgA antiserum 
(Biogenex Laboratories, San Ramon, CA, USA), 
synaptophysin, and proliferation-related Ki-67 antigen 
(Dako Cytomation Denmark A/S, Copenhagen, Denmark); 
as well as insulin, SST, glucagon and gastrin. Tumors were 
then classified following current guidelines [36].
Cell culture
In order to provide a biological basis for functional 
assays, previously validated NET cell lines were cultured. 
Specifically, carcinoid BON1 cells [38] and somatostatinoma-
derived QGP1 cells [39] were used. BON-1 was cultured in 
Dulbecco’s Modified Eagles Medium (DMEM-F12; Life 
Technologies, Barcelona, Spain) supplemented with 10% 
fetal bovine serum (FBS; Sigma-Aldrich, Madrid, Spain), 1% 
glutamine (Sigma-Aldrich) and 0.2% antibiotic (Gentamicin/
Amphotericin B; Life Technologies). QGP-1 was maintained 
in RPMI 1640 (Lonza, Basel, Switzerland), supplemented 
with 10% FBS, 1% glutamine and 0.2% antibiotic. Both cell 
lines were grown at 37ºC, in a humidified atmosphere with 
5.0% CO2.
RNA isolation and retrotranscription
Total RNA was isolated using TRIzol Reagent 
in the case of cell lines (Life Technologies) following 
the manufacturer’s instructions and treated with DNase 
(Promega, Barcelona, Spain). Total RNA extraction from 
paraffin samples was performed using RNeasy FFPE 
Kit (Qiagen, Limburg, Netherlands) according to the 
manufacturer’s protocol. The amount of RNA recovered 
(before and after DNase treatment) was determined using 
the NanoDrop2000 spectrophotometer (Thermo Scientific, 
Wilmington, NC, USA). Quality of RNA extracted was 
assessed by the same system using the Absorbance Ratio 
A260/280 and A260/230, requiring a minimum of 1.8 
on both to perform qPCR. One microgram of RNA was 
reverse transcribed to cDNA using random hexamer 
primers [First Strand Synthesis (Thermo Scientific)]. 
Quantitative real time PCR (qPCR)
qPCR reactions were performed using the Brilliant 
III SYBR Green Master Mix (Stratagene, La Jolla, CA, 
USA) in the Stratagene Mx3000p system for sst1-5, 
sst5TMD4, sst5TMD5 and their ligands somatostatin 
(SST) and cortistatin (CORT). For each reaction, 10 μl of 
master mix, 0.3 μl of each primer, 8.4 μl of distilled H2O 
and 1 μl of cDNA (50 ng) in a 20 μl total volume were 
mixed. Specifically, the program consisted of the following 
steps: (1) 95°C for 3 min, (2) 40 cycles of denaturing 
(95°C for 20 sec) and annealing/extension (61°C for 20 
sec) and (3) a last cycle where final PCR products were 
subjected to graded temperature-dependent dissociation 
(55°C to 95°C, increasing 0.5°C/30 sec) to verify 
that only one product was amplified. Specific primers 
(Supplementary Table 1) for human transcripts were 
designed with Primer3 software and StepOne™ Real-Time 
PCR System software v2.3 (Applied Biosystems®, Foster 
Oncotarget6604www.impactjournals.com/oncotarget
City, CA, USA). Results were validated as previously 
reported [40]. Samples were run in the same plate against 
a standard curve to estimate absolute mRNA copy number 
(1, 101, 102, 103, 104, 105, and 106 copies of synthetic 
cDNA template for each transcript), and a No-RT sample 
as a negative control. Normalization of all genes was done 
according to the value of beta-actin housekeeping gene. 
Results were presented as total copy number, adjusted for 
beta-actin. 
qPCR reactions for Ang-1, Ang-2, Tie-2 and VEGF 
were performed using LightCycler Detection System 
(Roche Diagnostics, Madrid, Spain) and LightCycler 
FastStart DNA Master SYBR Green I kit (Roche 
Diagnostics).
Immunohistochemistry and immunofluorescence 
studies
Immunohistochemistry was performed on formalin-
fixed paraffin-embedded sections. Tissue sections were 
dewaxed with xylene and rehydrated using decreasing 
concentrations of alcohol. Antigen retrieval was obtained 
by incubation in commercial 10 mM citrate solution 
(pH 6.0; Master Diagnostica, Granada, Spain) using a 
microwave oven for 15 min at maximum power (700 W). 
Prior to immunostaining, slides were cooled down to 
room temperature and endogenous peroxidase activity 
was removed by incubation with a peroxidase blocking 
solution (Methanol 3% H
2
O
2
) for 25 min, under gentle 
stirring. Then, sections were incubated overnight at 4ºC 
with rabbit polyclonal anti-sst5TMD4 antibody [12], goat 
polyclonal anti-Ang-1 (Cat. No. AF923, R&D Systems, 
Minneapolis, MN, USA), goat polyclonal anti-Ang-2 (Cat. 
No. AF623, R&D Systems), goat polyclonal anti-Tie-2 
(Cat. No. AF313, R&D Systems) and mouse monoclonal 
anti-CgA antibody (NBP2-33198AF488, Alexa Fluor 488, 
Novusbio Littleton, CO, USA) subsequently incubated 
with the appropriate HRP-conjugated secondary antibodies 
(Envision system, Dako, Barcelona, Spain). Finally, 
sections were developed with 3.3′-diaminobenzidine 
(Envision system 2-Solution DAB Kit), counterstained 
with Carazzi’s hematoxylin, dehydrated in alcohol, cleared 
with xylene, and mounted. Negative control reactions 
were performed by omitting the primary antibody from 
the dilution buffer. This resulted in a completed absence 
of staining in all cases. Sections were analyzed in a Nikon 
Eclipse E400 optical microscope (Nikon, Japan). 
A single histopathologist (MA), blinded to clinical 
data, scored all IHQ and IF cases. Tissue samples were 
scored manually using the immunohistochemical score 
method (IHS) proposed by Pinato et al. [41]. Specifically, 
for each sample, an IHS from 0 to 300 was assigned, based 
on the multiplication of the percentage of cells showing 
immunohistochemical expression (0–100) and the intensity 
of the signal (graded 1–3) in a minimum of 100 cells per 
slide. Every score was then re-assessed individually, and 
the mean of three readings was calculated.
Next, immunofluorescence techniques were 
performed to examine the pattern of staining and co-
expression of sst5TMD4, angiogenic markers and 
CgA. Tissue sections were dewaxed and antigen 
retrieval was performed as stated before, were 
blocked with normal human IgG and incubated 
with rabbit polyclonal anti-sst5TMD4 antibody, 
goat polyclonal anti-Ang-1 (Cat. No. AF923, R&D 
Systems, Minneapolis, MN, USA), goat polyclonal 
anti-Ang-2 (Cat. No. AF623, R&D Systems), goat 
polyclonal anti-Tie-2 (Cat. No. AF313, R&D Systems) 
and mouse monoclonal anti-CgA antibody (NBP2-
33198AF488, Alexa Fluor 488, Novusbio, Littleton, CO, 
USA) for one hour, followed by the proper secondary 
AlexaFluor 647 donkey-anti-goat (DAG) (Applied 
Biosystems, Carlsbad, CA, USA) and a biotinylated 
Donkey Anti Rabbit was used with Streptavidin-RhoX 
568 (Applied Biosystems, Carlsbad, CA, USA). Hoechst 
33342 dye was used for cell nuclei staining, and sections 
were analyzed in a Leica TCS-SP5 confocal microscope 
(Leica Microsystems, Wetzlar, Germany).
Stable transfection of the truncated receptor 
sst5TMD4
BON1 and QGP1 cell lines were stably transfected 
with sst5TMD4-containing pCDNA3.1+ vector (Life 
Technologies) and selected as previously reported [18]. 
Specifically, BON1 and QGP1 cells were seeded in 6-well 
culture plates and transfected with sst5TMD4 o empty 
(mock) vectors using Lipofectamine 2000 Transfection 
Reagent (Life Technologies) following manufacturer’s 
instructions and selected by geneticin treatment (Gibco, 
Barcelona, Spain). Stably-transfected cells were 
characterized by qPCR.
Alamar blue proliferation assay
Cell proliferation of transfected cell lines was 
measured by the Alamar Blue fluorescent assay (Life 
Technologies). Briefly, cells were seeded in 96-well plates 
at a density of 3,000-5,000/well. Basal, 24 h and 48 h cell 
viability was determined by measurement of fluorescent 
signal exciting at 560 nm and reading at 590 nm 
(Flex Station 3; Molecular Devices) at 570 nm. 
Specifically, the day of measurement, cells were incubated 
for 3 h in 10% alamar blue/ serum free-media, and then, 
alamar reduction was measured. Results are expressed as 
percentage vs. control (mock transfected cells). Medium 
was replaced by fresh medium immediately after each 
measurement. In all instances, cells were seeded per 
quadruplicate and all assays were repeated a minimum of 
four times.
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Migration capacity assay
The ability of mock and sst5TMD4 stably 
transfected cells to migrate was evaluated by wound 
healing technique. Briefly, stable cells were plated at 
sub-confluence in 6 well plates. Confluent cells were 
serum-starved for 24 h and after synchronization the 
wound was made using a 100 µl sterile pipette tip. Wells 
were rinsed in PBS and then cells were incubated for 24 h 
in FBS supplemented medium. Wound healing was 
calculated as the area of a rectangle centered in the picture 
24 h after the wound vs. the area of the rectangle just 
after doing the wound. At least three experiments were 
performed in independent days, in which three random 
pictures along the wound were acquired per well.
In vitro secretion assay and angiogenic marker 
expression
To determine serotonin and VEGF secretion, mock 
and sst5TMD4 stably transfected BON1 and QGP-1 cells 
were seeded in 12 wells plates. At 70% confluence, cells 
were serum starved and after 24 h incubation, media 
were collected and stored at −20°C until measurements. 
Secretion of serotonin was detected using a serotonin 
ELISA kit (ALPCO, Salem, NH, USA) and VEGF 
secretion by using a VEGF ELISA Kit (Thermo Scientific). 
Results were expressed as percentage of serotonin or 
VEGF secretion vs. control (mock transfected cells). In 
addition VEGF, Ang-1, Ang-2 and Tie-2 were measured 
in cell lines by qRT-PCR. At least four experiments were 
performed in independent days, where the cells were 
seeded per duplicate.
Statistical analysis
Descriptive results were expressed as mean ± standard 
deviation (SD), mean ± standard error of the mean (SEM), or 
median and minimum/maximum, as appropriate. Spearman’s 
bivariate correlations were performed for all quantitative 
variables and differences between groups were compared 
using analysis of variance (U-Mann Whitney or Kruskal-
Wallis ANOVA, as appropriate). Comparison between 
related variables was performed using Wilcoxon sum rank 
test. Samples from all groups within an experiment were 
processed at the same time. The p-values were two-sided and 
statistical significance was considered when p < 0.05, data 
is presented making specification for p < 0.05, p < 0.01 and 
p < 0.001. All statistical analyses were performed using SPSS 
version 20.0 (IBM SPSS Statistics Inc., Chicago, IL) and 
GraphPad version 5.0 (GraphPad Software, La Jolla, CA).
ACKNOWLEDGMENTS
We thank Francisca Molina-Jimenez from the 
Instituto Universitario Princesa for kindly giving 
technical assistance with confocal microscopy and, to the 
student Kiran van der Laan for supporting some of the 
experimental approaches included in this study. We also 
warmly thank all the participants included in the study for 
their selfless participation. 
FINANCIAL SUPPORT
This work has received the following grants: 
Proyectos de Investigación en Salud (FIS) PI13-01414, 
and PIE-0041 (funded by Instituto de Salud Carlos III) 
and S2011/BMD-2328 TIRONET (funded by Comunidad 
de Madrid) (to MM). BIO-0139, CTS-5051, CTS-1406, 
PI-0369-2012, BFU2010-19300, BFU2013-43282-R, 
PI13/00651, CIBERobn and Ayuda Merck Serono 2013 
(to RML and JPC). Fellowship CTS-5051 (to AIC). “Sara 
Borrell” program CD11/00276 (to MDG). CIBER is an 
initiative of Instituto de Salud Carlos III, Ministerio de 
Sanidad, Servicios Sociales e Igualdad, Spain.
Author contributions
MASN and ARL followed-up patients, developed 
the methodology of the study, acquired data, analyzed 
and interpreted data and wrote the manuscript. RML 
developed the methodology of the study, acquired data, 
analyzed and interpreted data and wrote the manuscript. 
MDG, AS and AVO developed the methodology of the 
study and provided technical support. MA reviewed tissue 
samples. EMP performed the surgery in all patients. MDC 
provided technical, administrative and material support. 
MM followed-up patients, contributed to study conception 
and design, interpreted data, supervised the study and 
revised the manuscript. JPC supervised the development 
of the methodology, contributed to study conception and 
design, interpreted data, supervised the study and revised 
the manuscript.
MASN, RML and ARL contributed equally to the 
study and should be considered co-first authors.
MM and JPC co-directed the study and should be 
considered co-senior authors.
CONFLICTS OF INTEREST
RML and JPC are members of the editorial 
board of the Journal of Clinical Endocrinology and 
Metabolism. RML has received research grants from 
Oncotarget6606www.impactjournals.com/oncotarget
Ipsen and speaker’s fees from Novartis and Ipsen. JPC 
has received research grants and speaker’s fees from 
Novartis and Ipsen, and is listed as inventor of patent 
PCT/ES2007/00627 for the commercial use of sst5TMD4. 
MDC is an employee of Ipsen. MM has received speaker’s 
fees from Novartis and Ipsen. The rest of the authors have 
nothing to disclose.
REFERENCES
 1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, 
Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, 
Krenning EP, Moss SF, Nilsson O, Rindi G, et al. 
Gastroenteropancreatic neuroendocrine tumours. Lancet 
Oncol. 2008; 9:61–72.
 2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, 
Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. 
One hundred years after “carcinoid”: Epidemiology of and 
prognostic factors for neuroendocrine tumors in 35,825 
cases in the united states. J Clin Oncol. 2008; 26:3063–72.
 3. Oberg K. Circulating biomarkers in gastroenteropancreatic 
neuroendocrine tumours. Endocr Relat Cancer. 2011; 18 
1:S17–25.
 4. Schally AV. Oncological applications of somatostatin 
analogues. Cancer Res. 1988; 48:6977–85.
 5. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. 
Octreotide. N Engl J Med. 1996; 334:246–54.
 6. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, 
Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, 
Harder J, Arnold C, Gress T, et al. Placebo-controlled, 
double-blind, prospective, randomized study on the effect 
of octreotide LAR in the control of tumor growth in 
patients with metastatic neuroendocrine midgut tumors: A 
report from the PROMID study group. J Clin Oncol. 2009; 
27:4656–63.
 7. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, 
Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, 
Rindi G, Langley A, Martinez S, et al. Lanreotide in 
metastatic enteropancreatic neuroendocrine tumors. N Engl J 
Med. 2014; 371:224–33.
 8. Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, 
Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, Scoazec 
JY. VEGF secretion by neuroendocrine tumor cells is 
inhibited by octreotide and by inhibitors of the PI3K/AKT/
mtor pathway. Neuroendocrinology. 2010; 91:268–78.
 9. Sidéris L, Dubé P, Rinke A. Antitumor effects of 
somatostatin analogs in neuroendocrine tumors. Oncologist. 
2012; 17:747–55.
10. Toumpanakis C, Caplin ME. Update on the role of 
somatostatin analogs for the treatment of patients with 
gastroenteropancreatic neuroendocrine tumors. Semin 
Oncol  2013; 40:56–68.
11. Keskin O, Yalcin S. A review of the use of somatostatin 
analogs in oncology. Onco Targets Ther. 2013; 6:471–83.
12. Durán-Prado M, Gahete MD, Martínez-Fuentes AJ, 
Luque RM, Quintero A, Webb SM, Benito-López P, Leal A, 
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